Trials / Completed
CompletedNCT00956436
Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)
A Phase 1b, Open-Label Study of Sorafenib With BIIB022 in Subjects With Advanced Hepatocellular Carcinoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 1b, open-Label study of sorafenib with BIIB022 in subjects with advanced hepatocellular carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BIIB022 | IV Q3W |
| DRUG | Sorafenib | Standard dosing of Sorafenib |
Timeline
- Start date
- 2009-08-01
- Primary completion
- 2011-04-01
- Completion
- 2011-04-01
- First posted
- 2009-08-11
- Last updated
- 2013-09-16
Locations
11 sites across 4 countries: United States, Singapore, Taiwan, United Kingdom
Source: ClinicalTrials.gov record NCT00956436. Inclusion in this directory is not an endorsement.